文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

无氧疗天数作为COVID-19及其他新发低氧血症治疗临床试验的结局指标

Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia.
PubMed 文献 · Chest · 2022-04-30
一句话结论无氧疗天数(OFDs)是融合死亡与新发补氧时长的复合终点,用于COVID-19等新发低氧血症人群的临床试验,其检验效能通常高于死亡率和无呼吸机天数,并已作为ACTIV-4 Host Tissue平台的主要终点。

急性与危重症临床试验历来以死亡率为主要终点,但死亡率终点需要大样本,且忽视患病率下降对患者的意义;COVID-19大流行凸显了对住院急性肺损伤患者开展快速高效试验的需求。无氧疗天数(OFDs)是融合死亡与新发补氧持续时间的复合终点,旨在刻画新发低氧血症和补氧使用高发人群中急性肺损伤的恢复情况,同时捕捉死亡与低氧性肺功能障碍两个以患者为中心的结局。检测OFDs差异的检验效能通常高于死亡率、无呼吸机天数等其他终点,OFDs已被选为第四项加速COVID-19治疗干预与疫苗(ACTIV-4)Host Tissue平台的主要终点,该平台评估针对COVID-19宿主反应的新疗法,纳入住院的COVID-19伴新发低氧血症成人。本文阐述使用OFDs作为临床试验终点的理由,提出定义与分析OFDs的标准化方法,并提供基于OFD终点的样本量计算框架。

要点

  • OFDs是死亡与新发补氧持续时间的复合终点,旨在刻画新发低氧血症和补氧使用高发人群中急性肺损伤的恢复情况。
  • 在COVID-19等新发低氧血症人群中,检测OFDs差异的检验效能通常高于死亡率、无呼吸机天数等其他临床试验终点。
  • OFDs是第四项加速COVID-19治疗干预与疫苗(ACTIV-4)Host Tissue平台的主要终点,该平台评估靶向COVID-19宿主反应的新疗法,纳入住院的COVID-19伴新发低氧血症成人。
  • 本文提出定义与分析OFDs的标准化方法,并提供基于OFD终点的样本量计算框架。

适用人群与场景

  • 住院的COVID-19伴新发低氧血症成人,为ACTIV-4 Host Tissue平台所评估的人群。
  • 新发低氧血症和补氧使用高发的人群,即急性肺损伤患者。

研究设计与关键结果

  • 本文为方法学文章,阐述以OFDs作为临床试验终点的理由,提出定义与分析OFDs的标准化方法,并提供基于OFD终点的样本量计算框架。
  • OFDs是融合死亡与新发补氧持续时间的复合终点,旨在刻画新发低氧血症和补氧使用高发人群中急性肺损伤的恢复情况。
  • 检测OFDs差异的检验效能通常高于死亡率、无呼吸机天数等其他临床试验终点。
  • OFDs是第四项加速COVID-19治疗干预与疫苗(ACTIV-4)Host Tissue平台的主要终点,该平台评估靶向COVID-19宿主反应的新疗法,纳入住院的COVID-19伴新发低氧血症成人。

证据类型、等级与局限

  • 证据类型:方法学文章(综述)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者提出OFDs可作为急性肺损伤临床试验的终点,用于新发低氧血症和补氧使用高发人群,以同时捕捉死亡与低氧性肺功能障碍两个以患者为中心的结局。
  • 作者指出,以死亡率为主要终点通常需要大样本,且仅关注死亡率不能体现降低患病率对患者生活的重要性;检测OFDs差异的检验效能通常高于死亡率、无呼吸机天数等其他终点。
  • 作者提出定义与分析OFDs的标准化方法,并提供基于OFD终点的样本量计算框架,供后续临床试验采用。

指南或共识出处

  • 第四项加速COVID-19治疗干预与疫苗(ACTIV-4)Host Tissue平台

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Mortality historically has been the primary outcome of choice for acute and critical care clinical trials. However, undue reliance on mortality can limit the scope of trials that can be performed. Large sample sizes are usually needed for trials powered for a mortality outcome, and focusing solely on mortality fails to recognize the importance that reducing morbidity can have on patients' lives. The COVID-19 pandemic has highlighted the need for rapid, efficient trials to rigorously evaluate new therapies for hospitalized patients with acute lung injury. Oxygen-free days (OFDs) is a novel outcome for clinical trials that is a composite of mortality and duration of new supplemental oxygen use. It is designed to characterize recovery from acute lung injury in populations with a high prevalence of new hypoxemia and supplemental oxygen use. In these populations, OFDs captures two patient-centered consequences of acute lung injury: mortality and hypoxemic lung dysfunction. Power to detect differences in OFDs typically is greater than that for other clinical trial outcomes, such as mortality and ventilator-free days. OFDs is the primary outcome for the Fourth Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4) Host Tissue platform, which evaluates novel therapies targeting the host response to COVID-19 among adults hospitalized with COVID-19 and new hypoxemia. This article outlines the rationale for use of OFDs as an outcome for clinical trials, proposes a standardized method for defining and analyzing OFDs, and provides a framework for sample size calculations using the OFD outcome.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Moskowitz A, Shotwell MS, Gibbs KW, et al. Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia. Chest. 2022. PMID: 35504307. doi:10.1016/j.chest.2022.04.145

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。